Despite the dramatic increase in the number of glioblastoma patients in the past decade and up-to-date treatments, brain tumors – especially glioblastomas – remain a disease with a poor outcome.
To change this pattern, the neuro-oncology team at the CHUV is intensely involved in international and in-house clinical trials. Clinical trials represent an important opportunity for patients who can potentially benefit from the latest advances in the field.
Over the last 10 years, the CHUV has offered over 30 trials for patients with glioblastoma. In 2021 alone, 60% of glioblastoma patients were included in a clinical trial at the CHUV. Patients admitted to the CHUV come from Europe, the Middle East, the United States and Russia for treatment.
Patients suffering from a brain tumor require specialized care from a large number of specialists. The CHUV is one of the few places in the world with highly trained specialists in each of the related fields who are exclusively dedicated to patient care and management through collaboration across disciplines to ensure that patients receive the most up-to-date care.
The clinical trials led by the neuro-oncology team have resulted in concrete advances in standards of care treatments, which are used worldwide today. These breakthrough contributions solidified the CHUV’s international reputation in this field.
The CHUV Foundation aims to get the community involved in supporting its treatment, research and training missions. The philanthropic gestures received at the Foundation aim to optimise patient care and develop scientific knowledge in the field of health for the good of all. Patients, their family and friends, the community and the medical and care staff are at the heart of its activities.